Search Within

Anthony R Mato

Formats
  1. Meeting Abstract (135)
  2. Journal Article (63)
  3. Review (16)
  4. Research Letter (10)
  5. Editorial (7)
  6. Guidelines (3)
  7. Book Section (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (236)
  2. Center for Hematologic Malignancies (236)
  3. Department of Medicine (236)
  4. Hematologic Malignancies, Division of (236)
  5. Hematology-Oncology Fellows (101)
  6. Lymphoma (47)

More Groups

People
  1. Lindsey Roeker (94)
  2. Andrew Zelenetz (33)
  3. Meghan Thompson (30)
  4. Omar Abdel-Wahab (19)
  5. Maria Palomba (18)
  6. Colleen Dorsey (14)

More People

Years
  1. 2025 (4)
  2. 2024 (2)
  3. 2023 (22)
  4. 2022 (49)
  5. 2021 (39)
  6. 2020 (52)

More Years

Publications
  1. Blood (82)
  2. Journal of Clinical Oncology (18)
  3. Clinical Lymphoma, Myeloma and Leukemia (16)
  4. Leukemia and Lymphoma (16)
  5. British Journal of Haematology (15)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (94)
  2. American Society of Clinical Oncology (19)
  3. Elsevier Inc. (18)
  4. Taylor & Francis Group (18)
  5. John Wiley & Sons (16)
  6. American Association for Cancer Research (10)

More Publishers

Results (236)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress)
    Meeting Abstract

    Hill, M.; Sharman, J. P.; Jurczak, W.; Coombs, C. C.; Wang, D.; Ku, N. C.; Guntur, A.; Shahda, S.; Leow, C. C.; Ghia, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • BRUIN CLL-322: A phase 3 open-label, randomized study of fixed-duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress)
    Meeting Abstract

    Wierda, W. G.; Pagel, J. M.; Davids, M. S.; Zinzani, P. L.; Lu, Y.; Liu, H.; Shahda, S.; Leow, C. C.; Tam, C. S.; Woyach, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Coombs, C. C.; Pagel, J. M.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)
    Meeting Abstract

    Kumar, S.; Kapoor, P.; Alencar, A.; Murthy, G. S. G.; Hoffmann, M.; Pagel, J.; Patel, V.; Pauff, J.; Zinzani, P. L.; Le Gouill, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • BRUIN CLL-314: A phase III open-label, randomized study of pirtobrutinib (LOXO-305) versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Woyach, J. A.; Wierda, W. G.; Coombs, C. C.; Lewis, K. L.; Gribben, J. G.; Escalon, M. P.; Ceccarelli, M.; Wu, X.; Mato, A. R.
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Enitociclib (VIP152/formerly BAY1251152) is a selective and active CDK9 inhibitor : Preliminary safety and early signs of efficacy in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Shadman, M.; Mato, A. R.; Batlevi, C. L.; Flinn, I. W.; Gutierrez, M.; Uemura, M.; Stevens, D. A.; Morillo, D.; Byrd, J. C.; Frigault, M. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed / refractory mantle cell lymphoma: Additional patients and extended follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A timelapse of patient and provider care perceptions and educational needs for CLL over three years of tailored educational interventions
    Meeting Abstract

    Ackbarali, T.; O'Brien, S.; Mato, A. R.; Davids, M. S.
    Blood (2022)

    Fulltext@MSK | Save
  • Assessing the burden of adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Seymour, J. F.; Byrd, J. C.; Munir, T.; Ghia, P.; Kater, A. P.; Chanan-Khan, A.; Furman, R. R.; O'Brien, S.; Brown, J. R.; Mato, A. R.; more...
    Blood (2022)

    Fulltext@MSK | Save